Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 11;15(11):e0242184.
doi: 10.1371/journal.pone.0242184. eCollection 2020.

Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients

Daniel Camprubí  1 , Alex Almuedo-Riera  1 , Helena Martí-Soler  1 , Alex Soriano  2 , Juan Carlos Hurtado  3 , Carme Subirà  1 , Berta Grau-Pujol  1 , Alejandro Krolewiecki  4 , Jose Muñoz  1
Affiliations

Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients

Daniel Camprubí et al. PLoS One. .

Erratum in

Abstract

Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19—Preliminary Report. New Engl J Med. 2020. 10.1056/NEJMoa2021436 - DOI - PMC - PubMed
    1. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—preliminary report. New Engl J Med. 2020. May 22 10.1056/NEJMoa2007764 - DOI - PubMed
    1. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020. 10.1001/jama.2020.6019 - DOI - PubMed
    1. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020:104787 10.1016/j.antiviral.2020.104787 - DOI - PMC - PubMed
    1. Chaccour C, Hamman F, Ramón-García S, Rabinovich NR. Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency. Am J Trop Med Hyg. 2020;00(0):1–2. - PMC - PubMed

MeSH terms